Nov 16 (Reuters) - Novartis AG:
* FDA APPROVES NOVARTIS DRUG PROMACTA FOR FIRST-LINE SAA AND GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR ADDITIONAL NEW INDICATION
* NOVARTIS AG - DECISION ON PROMACTA BY EUROPEAN MEDICINES AGENCY IS EXPECTED IN 2019
* NOVARTIS AG - PROMACTA RECEIVES FDA APPROVAL FOR FIRST-LINE TREATMENT OF SEVERE APLASTIC ANEMIA
* NOVARTIS AG - PROMACTA RECEIVES FDA APPROVAL FOR BREAKTHROUGH THERAPY DESIGNATION FOR LOW PLATELET COUNTS IN PEOPLE EXPOSED TO RADIATION Source text for Eikon: Further company coverage:
